title: Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus.
abstract: A novel interleukin-2 (IL-2)-dependent cell line, HANK1, was established from a patient with CD56+ NK/T-cell lymphoma arising in the retroperitoneum. Morphologically, HANK1 is a pleomorphic large cell line with irregular nuclei, which contains azurophilic granules in the cytoplasm. Immunophenotypic analysis showed that HANK1 expressed CD2, CD3epsilon, CD56, TIA-1, granzyme B, and HLA-DR, but no other T-lineage markers. These features were the same as seen in the original tumour, and are highly characteristic of nasal and 'nasal-type' NK/T-cell lymphoma as described in the proposed W.H.O. classification. Genotypically, this cell line also demonstrated the germline configuration of the T-cell receptor beta, gamma and the immunoglobulin heavy chain genes and clonal integration of the Epstein-Barr virus (EBV) together with antigen expression with a type II latency pattern (LMP-1+ and EBNA2-). Furthermore, Southern blot analysis using the EBV termini as probes confirmed its derivation from the original lymphoma, and revealed that it contained multiple copies of the EBV genome. Dose-dependent growth on IL-2 was observed in an in vitro study with a doubling time of 3 d at maximal stimulation. These data indicate that HANK1 seemed to preserve the biological characteristics of the original tumour and therefore may serve as a good model for the further analysis of unusual 'nasal-type' NK/T-cell lymphoma.
authors.affiliation: Department of Haematology and Chemotherapy, Aichi Cancer Centre Hospital, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kagami
authors.forename: S
authors.initials: S
authors.lastname: Nakamura
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Iida
authors.forename: Y
authors.initials: Y
authors.lastname: Yatabe
authors.forename: Y
authors.initials: Y
authors.lastname: Okada
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Tsurumi
authors.forename: M
authors.initials: M
authors.lastname: Seto
authors.forename: M
authors.initials: M
authors.lastname: Ogura
authors.forename: O
authors.initials: O
authors.lastname: Taguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
mesh_terms: D015139:Blotting, Southern; D015153:Blotting, Western; D018801:CD2 Antigens / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D002455:Cell Division; D002869:Chromosome Aberrations; D017809:Fatal Outcome; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007150:Immunohistochemistry; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000235:genetics / Q000473:pathology* / Q000821:virology; D008875:Middle Aged; D010641:Phenotype; D012186:Retroperitoneal Neoplasms / Q000235:genetics / Q000473:pathology* / Q000821:virology; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D018801:CD2 Antigens; D017252:CD3 Complex; D019002:CD56 Antigen; D007376:Interleukin-2